|
|
|||||||||||||||||||||||||||
|
Tetraphase Pharmaceuticals, Inc (TTPH) Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize tetracyclines for serious conditions, including bacterial infections caused by multidrug-resistant (MDR) bacteria. Co.'s product, Xerava (eravacycline), is an intravenous, antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections. In addition to Xerava, Co. has also developed other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846, a tetracycline for the treatment of acute myeloid leukemia.
|
|
|||||||||||||||||||||||||||
Free TTPH Email Alerts:
Tetraphase Pharmaceuticals, Inc (TTPH) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.